Rigel Pharmaceuticals, Inc.
1180 Veterans Boulevard
South San Francisco
About Rigel Pharmaceuticals, Inc.
Rigel Pharmaceuticals, Inc., is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. Rigel's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. Rigel's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy. In addition, Rigel has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics.
296 articles with Rigel Pharmaceuticals, Inc.
Rigel Pharmaceuticals, Inc. To Receive $5 Million Milestone Payment From Serono International S.A. For R763
Rigel Pharmaceuticals, Inc.'s R406/788 Shows Promise For Treating Immune Thrombocytopenia, Hemolytic Anemia And Myeloid Leukemia In Preclinical Studies
Rigel Pharmaceuticals, Inc. Announces Disappointing Results From Phase II Study Of R112 For The Treatment Of Allergic Rhinitis
Rigel Pharmaceuticals, Inc. Announces Presentation Of Phase I Data On R406/788 At The American College of Rheumatology Annual Meeting
Rigel Pharmaceuticals, Inc. Announces Publications Highlighting Two New Screening Mechanisms For Ubiquitin Ligase Inhibitors
Rigel Pharmaceuticals, Inc. Announces Presentations At American College of Allergy, Asthma and Immunology (ACAAI) Annual Meeting